Manufacturer

Country

Certificates

Registration Date	28 Jan 2015
Share

BRILINTA

(0)

Medicine Pharmaceuticals Product Number : 0186-0776-60

Platelet Aggregation Inhibitors

Drug Information

Generic

ticagrelor

NDC Code

0186-0776-60

Drug Class

ADP-Induced Aggregation Inhibitor

Therapeutic Class

Platelet aggregation inhibitors

Dosage form

tablet

Route of Administration

Oral

Therapeutic Area

1.acute coronary syndromes (ACS)

Indication

"BRILINTA is indicated to reduce the rate of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI). For at least the first 12 months following ACS, it is superior to clopidogrel. BRILINTA also reduces the rate of stent thrombosis in patients who have been stented for treatment of ACS. (reduction of thrombotic events in patients with acute coronary syndrome) "